DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $398,000 | -62.5% | 1,356 | -57.9% | 0.14% | -22.0% |
| Q4 2021 | $1,060,000 | -16.1% | 3,221 | -22.4% | 0.19% | -63.3% |
| Q3 2021 | $1,263,000 | -75.8% | 4,150 | -78.7% | 0.51% | -60.8% |
| Q2 2021 | $5,224,000 | +19.0% | 19,468 | -0.2% | 1.29% | +12.2% |
| Q1 2021 | $4,389,000 | +1.8% | 19,501 | +0.5% | 1.15% | -24.9% |
| Q4 2020 | $4,311,000 | -1.6% | 19,406 | -4.7% | 1.54% | -8.4% |
| Q3 2020 | $4,383,000 | +23.8% | 20,354 | +1.7% | 1.68% | +10.6% |
| Q2 2020 | $3,539,000 | +26.9% | 20,012 | -0.6% | 1.52% | +2.8% |
| Q1 2020 | $2,788,000 | -9.9% | 20,142 | -0.1% | 1.47% | +22.4% |
| Q4 2019 | $3,094,000 | +4.6% | 20,157 | -1.6% | 1.20% | -9.7% |
| Q3 2019 | $2,959,000 | -0.3% | 20,487 | -1.4% | 1.33% | -1.3% |
| Q2 2019 | $2,969,000 | +7.4% | 20,772 | -0.8% | 1.35% | +9.8% |
| Q1 2019 | $2,765,000 | +27.8% | 20,946 | -0.2% | 1.23% | +12.7% |
| Q4 2018 | $2,164,000 | -8.7% | 20,983 | -3.8% | 1.09% | +8.4% |
| Q3 2018 | $2,371,000 | +9.8% | 21,822 | -0.3% | 1.01% | +3.4% |
| Q2 2018 | $2,159,000 | +0.7% | 21,882 | -0.1% | 0.97% | +1.5% |
| Q1 2018 | $2,144,000 | +4.7% | 21,896 | -0.7% | 0.96% | +23.3% |
| Q4 2017 | $2,047,000 | +1.3% | 22,046 | -6.4% | 0.78% | -9.5% |
| Q3 2017 | $2,020,000 | +1.5% | 23,546 | -0.2% | 0.86% | -1.8% |
| Q2 2017 | $1,991,000 | -1.8% | 23,587 | -0.5% | 0.88% | -23.2% |
| Q1 2017 | $2,027,000 | +9.9% | 23,694 | 0.0% | 1.14% | +1.2% |
| Q4 2016 | $1,844,000 | -0.5% | 23,694 | +0.2% | 1.13% | -12.7% |
| Q3 2016 | $1,854,000 | -45.7% | 23,653 | -30.0% | 1.29% | -32.1% |
| Q2 2016 | $3,412,000 | -1.1% | 33,780 | -7.1% | 1.90% | -14.1% |
| Q1 2016 | $3,451,000 | +1.1% | 36,380 | -1.0% | 2.21% | +0.4% |
| Q4 2015 | $3,414,000 | +3.3% | 36,752 | -5.3% | 2.21% | -0.7% |
| Q3 2015 | $3,306,000 | -1.1% | 38,804 | -0.6% | 2.22% | +10.2% |
| Q2 2015 | $3,343,000 | -9.4% | 39,054 | -10.2% | 2.02% | -7.4% |
| Q1 2015 | $3,691,000 | -1.2% | 43,479 | -0.2% | 2.18% | -2.6% |
| Q4 2014 | $3,735,000 | +9.9% | 43,579 | -2.6% | 2.24% | -0.1% |
| Q3 2014 | $3,400,000 | -3.9% | 44,749 | -0.4% | 2.24% | -5.6% |
| Q2 2014 | $3,539,000 | +4.9% | 44,949 | -0.1% | 2.37% | +0.2% |
| Q1 2014 | $3,375,000 | -3.2% | 44,999 | -0.3% | 2.37% | -3.5% |
| Q4 2013 | $3,486,000 | +9.9% | 45,151 | -1.3% | 2.45% | -0.5% |
| Q3 2013 | $3,171,000 | +9.4% | 45,751 | -0.1% | 2.47% | +4.4% |
| Q2 2013 | $2,898,000 | – | 45,786 | – | 2.36% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |